Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDCB
Discontinued Product
1952 has been discontinued.
View all Glutamate (Metabotropic) Group I Receptors products.
Description: Allosteric modulator of mGlu5 receptors
Alternative Names: 3,3'-Dichlorobenzaldazine
Chemical Name: [(3-Chlorophenyl)methylene]hydrazone-3-chlorobenzaldehyde
Purity: ≥98% (HPLC)
Biological Activity for DCB
Allosteric ligand for the metabotropic glutamate receptor mGlu5; displays neutral modulation. Does not affect agonist-stimulated mGlu5 responses, but blocks regulation of the receptor by other allosteric modulators such as DFB (Cat. No. 1625) and DMeOB (Cat. No. 1953).
Technical Data for DCB
| M. Wt | 277.15 |
| Formula | C14H10Cl2N2 |
| Storage | Desiccate at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 6971-97-7 |
| PubChem ID | 9604992 |
| InChI Key | IVDUVYRBLGSJAO-UHFFFAOYSA-N |
| Smiles | ClC1=CC(=CC=C1)\N=C\N=C\C1=CC(Cl)=CC=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for DCB
References for DCB
References are publications that support the biological activity of the product.
O'Brien et al (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol.Pharmacol. 64 731 PMID: 12920211
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group I Receptor Modulators
Keywords: DCB, DCB supplier, Allosteric, modulators, mGlu5, mGluR5, Group, I, Receptors, Glutamate, Metabotropic, 3,3'-Dichlorobenzaldazine, (Metabotropic), 1952, Tocris Bioscience
Citations for DCB
Citations are publications that use Tocris products.
Currently there are no citations for DCB.
Reviews for DCB
There are currently no reviews for this product. Be the first to review DCB and earn rewards!
Have you used DCB?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.